IP Library Granted Patent US 10,508,138
Granted Patent B2
US 10,508,138 · App. 15/737,937 · Granted Dec 17, 2019

Polypeptide capable of binding to vascular endothelial growth factor, and use thereof

Inventors: Hak-Sung Kim (Daejeon, KR); Da Eun Hwang (Daejeon, KR); Jeong Hyun Ryou (Daejeon, KR)
Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
C07K14/461A61P27/02A61P35/00A61K38/00C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,508,138
App. No.
15/737,937
Granted
Dec 17, 2019
Kind
B2
Abstract

The present disclosure relates to a novel polypeptide capable of binding specifically to vascular endothelial growth factor, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a recombinant microorganism including the expression vector, a method of producing the polypeptide using the recombinant microorganism, a composition for treating or preventing age-related macular degeneration or cancer, which comprises the polypeptide, and a method for preventing or treating age-related macular degeneration or cancer, which comprises administering the composition for treating or preventing age-related macular degeneration or cancer, which comprises the polypeptide. The disclosed polypeptide is capable of binding to vascular endothelial growth factor to inhibit the activity thereof, and thus can be widely used as an agent for treating and preventing various diseases associated with vascular endothelial growth factor (VEGF).

Claims (3)

1. A polypeptide capable of binding to vascular endothelial growth factor (VEGF) comprising the amino acid sequence of any one of SEQ ID NOs: 3 to 8.

2. The polypeptide of claim 1 , wherein the polypeptide inhibits the activity of VEGF upon binding thereof.

3. A composition for treating age-related macular degeneration, comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

Assignments (3)
CHANGE OF NAME Recorded Nov 11, 2020
From: REPIGEN
To: PROEN THERAPEUTICS INC.
Reel/Frame 054388/0422 →
LICENSE Recorded Jun 17, 2019
From: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
To: REPIGEN
Reel/Frame 049488/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2018
From: KIM, HAK-SUNG; HWANG, DA EUN; RYOU, JEONG HYUN
To: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Reel/Frame 045922/0940 →
Priority Claims (1)
KR 10-2015-0087476 · Jun 19, 2015 · national
Continuity (1)
Related Publication 20180170980A1 · Jun 21, 2018